IDEAS home Printed from https://ideas.repec.org/p/akf/cafewp/36.html

The role of Health Technology Assessment in reimbursement decisions and pricing of new medicines across diverse healthcare systems

Author

Listed:
  • Perin, Fernanda

Abstract

The rising costs of innovative medicines present a major challenge for public healthcare systems, particularly in countries striving for universal health coverage. Health Technology Assessment (HTA) is critical in guiding reimbursement decisions and negotiating medicine prices, particularly in monopoly markets where pharmaceutical companies hold exclusive rights due to patent protection. This study examines how eight healthcare systems – England, Australia, Canada, Germany, Colombia, Mexico, India, and Brazil – utilise HTA in price negotiations for new medicines. By analysing the integration of HTA into pricing mechanisms, decision-making criteria, and economic evaluation methods, this research highlights significant disparities in terms of socioeconomic context, healthcare system management, and HTA maturity. These insights offer valuable policy recommendations for optimising HTA’s role in controlling medicine prices and ensuring sustainable healthcare financing.

Suggested Citation

  • Perin, Fernanda, 2025. "The role of Health Technology Assessment in reimbursement decisions and pricing of new medicines across diverse healthcare systems," CAFE Working Papers 36, Centre for Accountancy, Finance and Economics (CAFE), Birmingham City Business School, Birmingham City University.
    • Handle: RePEc:akf:cafewp:36
    as

    Download full text from publisher

    File URL: https://www.open-access.bcu.ac.uk/16465/1/Perin%20-%20WP36%20CAFE%20-%20HTA%20medicine%20reimbursement%20and%20pricing.pdf
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Mariana Mazzucato & Victor Roy, 2019. "Rethinking value in health innovation: from mystifications towards prescriptions," Journal of Economic Policy Reform, Taylor and Francis Journals, vol. 22(2), pages 101-119, April.
    2. Rosa, Rodriguez-Monguio & Alberto, Infante Campos, 2004. "Universal health care for Colombians 10 years after Law 100: challenges and opportunities," Health Policy, Elsevier, vol. 68(2), pages 129-142, May.
    3. Mariana Mazzucato & Victor Roy, 2019. "Rethinking value in health innovation: from mystifications towards prescriptions," Journal of Economic Policy Reform, Taylor & Francis Journals, vol. 22(2), pages 101-119, April.
    4. CHENG, Nianliang & LI, Hongxia & MENG, Fan & CHAI, Fahe, 2015. "Overview of Urban PM2.5 Numerical Forecast Models in China," Asian Agricultural Research, USA-China Science and Culture Media Corporation, vol. 7(10), pages 1-7, October.
    5. Tubychko K.V. & Zaruba V.Y. & Pignasty O.M. & Khodusov V.D., 2015. "The overview of manufactured systems models," Економічний вісник Донбасу Экономический вестник Донбасса, CyberLeninka;Институт экономики промышленности НАН Украины, issue 4 (42), pages 151-161.
    6. Carlson, Josh J. & Sullivan, Sean D. & Garrison, Louis P. & Neumann, Peter J. & Veenstra, David L., 2010. "Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers," Health Policy, Elsevier, vol. 96(3), pages 179-190, August.
    7. Akudinobi B.E.B. & Egboka B.C.E. & Moore C. & Obiadi I.I., 2015. "Critical Overview of Some Pumping Test Analysis Equations," Scientific Review, Academic Research Publishing Group, vol. 1(7), pages 135-142, 12-2015.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Habib, A. & Ranasinghe, D. & Huang, H.J., 2018. "A literature survey of financial reporting in private firms," Research in Accounting Regulation, Elsevier, vol. 30(1), pages 31-37.
    2. Susan K. Sell, 2020. "What COVID-19 Reveals About Twenty-First Century Capitalism: Adversity and Opportunity," Development, Palgrave Macmillan;Society for International Deveopment, vol. 63(2), pages 150-156, December.
    3. Walsh, P.P. & Murphy, E. & Horan, D., 2020. "The role of science, technology and innovation in the UN 2030 agenda," Technological Forecasting and Social Change, Elsevier, vol. 154(C).
    4. Luca Papi & Riccardo Ievoli & Giorgia Gobbo & Enrico Deidda Gagliardo & Lamberto Manzoli, 2021. "Performance governance per la generazione di Valore Pubblico in sanit?. Evidenze empiriche dalle aziende sanitarie dell?Emilia-Romagna," MECOSAN, FrancoAngeli Editore, vol. 0(117), pages 27-58.
    5. Llewellyn, Sue & Begkos, Christos & Ellwood, Sheila & Mellingwood, Chris, 2022. "Public value and pricing in English hospitals: Value creation or value extraction?," CRITICAL PERSPECTIVES ON ACCOUNTING, Elsevier, vol. 85(C).
    6. Susan K. Sell, 2021. "21st Century Capitalism and Innovation for Health," Global Policy, London School of Economics and Political Science, vol. 12(S6), pages 12-20, July.
    7. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    8. Bhardwaj, Ramesh, 2015. "Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value," MPRA Paper 63405, University Library of Munich, Germany.
    9. Rositsa Koleva-Kolarova & James Buchanan & Heleen Vellekoop & Simone Huygens & Matthijs Versteegh & Maureen Rutten-van Mölken & László Szilberhorn & Tamás Zelei & Balázs Nagy & Sarah Wordsworth & Apos, 2022. "Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options," Applied Health Economics and Health Policy, Springer, vol. 20(4), pages 501-524, July.
    10. Shuli Brammli-Greenberg & Ira Yaari & Elad Daniels & Ariella Adijes-Toren, 2021. "How Managed Entry Agreements can improve allocation in the public health system: a mechanism design approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 699-709, July.
    11. Evgeni Dvortsin & Judith Gout-Zwart & Ernst-Lodewijk Marie Eijssen & Jan van Brussel & Maarten J Postma, 2016. "Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer," PLOS ONE, Public Library of Science, vol. 11(1), pages 1-12, January.
    12. Marcelien H. E. Callenbach & Rick A. Vreman & Aukje K. Mantel-Teeuwisse & Wim G. Goettsch, 2022. "When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs," IJERPH, MDPI, vol. 20(1), pages 1-12, December.
    13. Bonny Parkinson & Rosalie Viney & Marion Haas & Stephen Goodall & Preeyaporn Srasuebkul & Sallie-Anne Pearson, 2016. "Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer," PharmacoEconomics, Springer, vol. 34(10), pages 1039-1050, October.
    14. Fernando Antonanzas & Carmelo Juárez-Castelló & Reyes Lorente & Roberto Rodríguez-Ibeas, 2019. "The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments," PharmacoEconomics, Springer, vol. 37(12), pages 1469-1483, December.
    15. Morgan, Steven G. & Thomson, Paige A. & Daw, Jamie R. & Friesen, Melissa K., 2013. "Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers," Health Policy, Elsevier, vol. 112(3), pages 248-254.
    16. Andrew M. Jones (ed.), 2012. "The Elgar Companion to Health Economics, Second Edition," Books, Edward Elgar Publishing, number 14021, August.
    17. Dunlop, William C.N. & Staufer, Alexandra & Levy, Pierre & Edwards, Guy J., 2018. "Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience," Health Policy, Elsevier, vol. 122(5), pages 528-532.
    18. repec:bla:glopol:v:8:y:2017:i:s2:p:46-59 is not listed on IDEAS
    19. Bengt Jönsson, 2011. "Relative effectiveness and the European pharmaceutical market," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(2), pages 97-102, April.
    20. Alessandra Ferrario & Diāna Arāja & Tomasz Bochenek & Tarik Čatić & Dávid Dankó & Maria Dimitrova & Jurij Fürst & Ieva Greičiūtė-Kuprijanov & Iris Hoxha & Arianit Jakupi & Erki Laidmäe & Olga Löblová , 2017. "The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications," PharmacoEconomics, Springer, vol. 35(12), pages 1271-1285, December.
    21. Taryn A. G. Quinlan & Brock Schroeder & Sue Kwon & Jane F. Barlow & Michael S. Sherman & Heather D. Anderson & Garth Wright & R. Brett McQueen, 2021. "Economic Impact of Coverage Expansion for Non-invasive Prenatal Testing Through a Performance-Based Risk-Sharing Agreement," PharmacoEconomics - Open, Springer, vol. 5(3), pages 449-458, September.

    More about this item

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:akf:cafewp:36. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Research Publications Librarian (email available below). General contact details of provider: https://edirc.repec.org/data/bsuceuk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.